{"product_id":"nxerapharma-pestle-analysis","title":"Nxera Pharma PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Shortcut to Market Insight Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eGain strategic clarity with our PESTLE Analysis of Nxera Pharma—uncover how political shifts, regulatory pressures, economic trends, and technological advances will shape its trajectory and competitive standing. This concise yet powerful brief highlights risks and opportunities investors and strategists need now. Purchase the full, ready-to-use report for detailed insights, data-backed scenarios, and actionable recommendations. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Drug Pricing Legislation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe US Inflation Reduction Act enables Medicare drug price negotiation starting 2026, potentially lowering prices for top-selling therapies by up to 60%, while EU moves (Germany, UK) tighten price controls and reference pricing—these shifts could compress peak sales forecasts for Nxera Pharma’s GPCR-targeted neurologic candidates, where orphan designations (affecting ~5–10% of neurology drugs) and payer negotiation power will determine net pricing and long-term EBITDA margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical R\u0026amp;D Collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs a UK–Japan operator, Nxera Pharma depends on post-Brexit trade agreements and the UK–Japan Comprehensive Economic Partnership (effective 2021) to ease tariffs and regulatory alignment for cross-border R\u0026amp;D; UK–Japan goods trade reached £33.1bn in 2023, underscoring material flows relevant to supply chains.\u003c\/p\u003e\n\u003cp\u003ePolitical stability and bilateral investment treaties support capital and talent mobility—Japan’s skilled migration rose 12% in 2024—critical for Nxera’s drug-discovery teams across both hubs.\u003c\/p\u003e\n\u003cp\u003eAny diplomatic disruption could impede IP transfers and lab asset deployment: international patent filings between the UK and Japan totaled roughly 18,000 in 2022, highlighting scale at risk from policy shifts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Healthcare Funding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePublic sector investment in neurodegenerative research underpins clinical-stage biopharma; in 2024 US federal funding for Alzheimer's and related dementias reached about $3.1 billion, supporting preclinical and clinical partnerships relevant to Nxera Pharma.\u003c\/p\u003e\n\u003cp\u003ePolitical agendas prioritizing Alzheimer's and Parkinson's can expand grant pools and academic collaborations, with NIH awards to neurodegeneration rising ~8% year-over-year into 2024.\u003c\/p\u003e\n\u003cp\u003eConversely, policy shifts toward infectious disease or other priorities risk diverting funds, as seen when pandemic response reallocated billions from chronic disease research during 2020–2022.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Harmonization Initiatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePolitical efforts via the ICH to harmonize standards—now covering 17 guideline areas—accelerate Nxera Pharma's time-to-market by aligning requirements across FDA, EMA and PMDA, potentially cutting multi-region approval prep by an estimated 12–18% based on industry benchmarking through 2024–2025.\u003c\/p\u003e\n\u003cp\u003eStreamlined regulatory convergence reduces administrative overhead for multi-regional trials, lowering per-trial compliance costs which the industry reports fell ~10% between 2021–2024, aiding Nxera's global development efficiency.\u003c\/p\u003e\n\u003cp\u003eOngoing political support for expedited pathways for unmet needs—reflected in 25% of FDA oncology approvals using accelerated programs in 2024—remains a key driver of Nxera's projected development timelines into late 2025.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eICH harmonization may cut approval prep 12–18%\u003c\/li\u003e\n\u003cli\u003eCompliance costs down ~10% (2021–2024)\u003c\/li\u003e\n\u003cli\u003e25% of FDA oncology approvals used accelerated programs in 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTrade Policy and Supply Chains\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTariffs and trade restrictions on lab equipment and reagents have raised input costs; US tariffs and export controls contributed to a ~5–8% price increase for specialty reagents in 2024, squeezing Dxera-like R\u0026amp;D budgets.\u003c\/p\u003e\n\u003cp\u003ePolitical moves toward friend-shoring—reshoring to trusted partners—shift sourcing away from China, raising supply-chain redundancy but adding 6–12% logistic and manufacturing premiums for pharmaceutical components in 2024–25.\u003c\/p\u003e\n\u003cp\u003eNxera must adapt supplier diversification, local sourcing, and inventory buffers to prevent delays to structural biology and chemistry platforms and avoid capex or opex spikes that could erode R\u0026amp;D timelines.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTariff-driven reagent price rise: ~5–8% (2024)\u003c\/li\u003e\n\u003cli\u003eFriend-shoring premium: ~6–12% added costs (2024–25)\u003c\/li\u003e\n\u003cli\u003eMitigation: supplier diversification, local sourcing, safety stock\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDrug pricing cuts, trade shifts and R\u0026amp;D funding reshape pharma costs and approvals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMedicare negotiation (IRA) may cut top-drug prices up to 60% from 2026; UK–Japan trade (£33.1bn 2023) and post-Brexit rules affect supply\/R\u0026amp;D; US neuro research funding ~$3.1bn (2024) and NIH +8% YOY support partnerships; tariffs\/friend-shoring raised reagent\/logistics costs ~5–12% (2024–25), while ICH harmonization and expedited pathways shave ~12–18% approval prep and speed timelines.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare negotiation impact\u003c\/td\u003e\n\u003ctd\u003eUp to -60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUK–Japan trade 2023\u003c\/td\u003e\n\u003ctd\u003e£33.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS neuro funding 2024\u003c\/td\u003e\n\u003ctd\u003e$3.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReagent\/logistics cost rise\u003c\/td\u003e\n\u003ctd\u003e~5–12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eICH prep reduction\u003c\/td\u003e\n\u003ctd\u003e12–18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how Political, Economic, Social, Technological, Environmental, and Legal forces uniquely impact Nxera Pharma, with each section backed by current data and trends to surface actionable risks and opportunities for executives, investors, and strategists.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, shareable PESTLE snapshot of Nxera Pharma that highlights regulatory, market, and technological risks and opportunities for quick alignment in meetings or client reports.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest Rate Environment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of late 2025, global policy rates remain elevated—US Fed funds ~5.25–5.50% and ECB refi ~4.25%—raising Nxera Pharma’s cost of capital and discount rates used in DCFs, which compresses valuations for clinical-stage biotech with long cash‑burn horizons.\u003c\/p\u003e\n\u003cp\u003eHigher rates make equity financing more dilutive and debt more expensive; analysts should model longer financing needs given Nxera’s pre‑revenue status and 12–24 month cash runway assumptions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency Exchange Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNxera Pharma operates across Japan, the UK and the US, making its top-line sensitive to JPY\/GBP\/USD swings; 2024 saw the USD\/JPY range about 132–153 and GBP\/USD 1.20–1.35, amplifying FX risk on milestone payments. \u003c\/p\u003e\n\u003cp\u003eWith milestone revenues often invoiced in foreign currency while R\u0026amp;D and manufacturing costs are local, exchange moves created material accounting gains\/losses—biotech peers reported FX impacts of up to 8–12% of EBITDA in 2024. \u003c\/p\u003e\n\u003cp\u003eRobust hedging—forwards, options and natural hedges—plus rolling cash-flow forecasts are essential to preserve Nxera’s cash runway and limit downside from adverse currency shifts. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMilestone Payment Dependency\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe company’s economic stability hinges on securing clinical and regulatory milestones from Big Pharma partners, with Nxera reporting potential milestone payments up to $420 million across deals as of 2025, which directly fund R\u0026amp;D without equity dilution. These non-dilutive payments reduced Nxera’s 2024 external financing needs by an estimated 35%, lowering cash burn pressure. Analysts monitor milestone triggers as leading economic indicators of solvency and capacity to sustain long-term research operations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBio-Pharmaceutical R\u0026amp;D Inflation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRising costs for specialized labor, trial recruitment and advanced lab tech squeeze Nxera’s margins; US biotech wage growth averaged 6.2% in 2024 in major hubs, driving payroll inflation. Phase II\/III per-patient costs rose ~8%–12% in 2023–24, raising cash needs and pushing some programs toward partnering.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e6.2% biotech wage growth (2024)\u003c\/li\u003e\n\u003cli\u003ePhase II\/III per-patient cost +8%–12% (2023–24)\u003c\/li\u003e\n\u003cli\u003eHigher recruitment costs lengthen timelines\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVenture Capital and Equity Appetite\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBroader economic sentiment shapes follow-on financing for clinical-stage biotech: in 2024 global VC funding to life sciences rose to about $62.5B, easing capital access for high-upside GPCR discovery platforms like Nxera.\u003c\/p\u003e\n\u003cp\u003eDuring bull cycles investors favor early-stage platforms; 2023–2025 public biotech IPO windows showed 40–60% higher valuations versus bear phases, enhancing partnership leverage for Nxera.\u003c\/p\u003e\n\u003cp\u003eNxera must time capital raises and collaboration announcements to market cycles to maximize valuation and reduce dilution risk.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 global life sciences VC: ~$62.5B\u003c\/li\u003e\n\u003cli\u003eIPO valuation uplift in bull windows: 40–60%\u003c\/li\u003e\n\u003cli\u003eStrategy: align fundraising and partnership news with bullish biotech sentiment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigher rates, FX swings and rising biotech costs squeeze Nxera’s valuation and cash runway\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eElevated 2025 policy rates (Fed 5.25–5.50%, ECB 4.25%) raise Nxera’s discount rates, pressuring valuations and making equity\/debt costlier; 2024 USD\/JPY 132–153 and GBP\/USD 1.20–1.35 amplified FX risk versus milestone receipts (potential $420M). 2024 biotech wage growth ~6.2% and Phase II\/III per‑patient cost +8–12% increased cash burn; 2024 life‑sciences VC ~$62.5B.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFed rate (2025)\u003c\/td\u003e\n\u003ctd\u003e5.25–5.50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUSD\/JPY (2024)\u003c\/td\u003e\n\u003ctd\u003e132–153\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWage growth (2024)\u003c\/td\u003e\n\u003ctd\u003e6.2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVC funding (2024)\u003c\/td\u003e\n\u003ctd\u003e$62.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eNxera Pharma PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact document you’ll receive after purchase—fully formatted and ready to use, presenting a concise PESTLE analysis of Nxera Pharma covering political, economic, social, technological, legal, and environmental factors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751543648633,"sku":"nxerapharma-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/nxerapharma-pestle-analysis.png?v=1772232820","url":"https:\/\/matrixbcg.com\/products\/nxerapharma-pestle-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}